Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan To Lower Price Caps On Key Prescription Drugs

This article was originally published in PharmAsia News

Executive Summary

Japan plans new price caps on prescription drugs in April, lowered by an average of 5.2 percent. Some of the most popular drugs produced by major drug makers face an even steeper reduction in the maximum price allowed, by 10.1 percent. The new caps are expected to cause more pharmaceutical makers to shift their focus from marketing drugs in Japan to other countries. Among drugs facing the greatest price reduction are those in a new generation of medicines to lower blood pressure, including Takeda's Blopress (candesartan cilexetil), Astellas' Micardis (telmisartan) and Daiichi Sankyo's Olmetec (olmesartan). (Click here for more - a subscription may be required

You may also be interested in...



Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm

Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

Helius Seeks FDA De Novo For Portable Neuromodulation Stimulator For MS Patients

The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel